Alejandro Sifrim

Alejandro Sifrim

Auto-generated profile, based on publicly available information

Alejandro Sifrim

KU Leuven

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2015 in The Lancet
Verified
Journal Article
Open access
CWCaroline F Wright
Caroline F Wright
TFTomas W Fitzgerald
Tomas W Fitzgerald
WJWendy D Jones
Wendy D Jones
SCStephen Clayton
Stephen Clayton
JMJeremy F McRae
Jeremy F McRae
HFHelen V Firth
Helen V Firth
Human genome sequencing has transformed our understanding of genomic variation and its relevance to health and disease, and is now starting to enter clinical practice for the diagnosis of rare diseases. The question of whether and how some categories of genomic findings should be shared with individual research participants is currently a topic of international debate, and development of robust analytical workflows to identify and communicate clinically relevant variants is paramount. The Deciphering Developmental Disorders (DDD) study has developed a UK-wide patient recruitment network involving over 180 clinicians across all 24 regional genetics services, and has performed genome-wide microarray and whole exome sequencing on children with undiagnosed developmental disorders and their parents. After data analysis, pertinent genomic variants were returned to individual research participants via their local clinical genetics team. Around 80,000 genomic variants were identified from exome sequencing and microarray analysis in each individual, of which on average 400 were rare and predicted to be protein altering. By focusing only on de novo and segregating variants in known developmental disorder genes, we achieved a diagnostic yield of 27% among 1133 previously investigated yet undiagnosed children with developmental disorders, whilst minimising incidental findings. In families with developmentally normal parents, whole exome sequencing of the child and both parents resulted in a 10-fold reduction in the number of potential causal variants that needed clinical evaluation compared to sequencing only the child. Most diagnostic variants identified in known genes were novel and not present in current databases of known disease variation. Implementation of a robust translational genomics workflow is achievable within a large-scale rare disease research study to allow feedback of potentially diagnostic findings to clinicians and research participants. Systematic recording of relevant clinical data, curation of a gene-phenotype knowledge base, and development of clinical decision support software are needed in addition to automated exclusion of almost all variants, which is crucial for scalable prioritisation and review of possible diagnostic variants. However, the resource requirements of development and maintenance of a clinical reporting system within a research setting are substantial. Health Innovation Challenge Fund, a parallel funding partnership between the Wellcome Trust and the UK Department of Health.

1 August 2016 in Nature Genetics
Verified
Journal Article
Open access
PDF file
ASAlejandro Sifrim
Alejandro Sifrim
MHMarc-Phillip Hitz
Marc-Phillip Hitz
AWAnna Wilsdon
Anna Wilsdon
JBJeroen Breckpot
Jeroen Breckpot
STSaeed H Al Turki
Saeed H Al Turki
MHMatthew E Hurles
Matthew E Hurles
Matthew Hurles and colleagues report exome sequencing of 1,891 individuals with syndromic or nonsyndromic congenital heart defects (CHD). They found that nonsyndromic CHD patients were enriched for protein-truncating variants in CHD-associated genes inherited from unaffected parents and identified three new syndromic CHD disorders caused by de novo mutations. Congenital heart defects (CHDs) have a neonatal incidence of 0.8–1% (refs. 1,2). Despite abundant examples of monogenic CHD in humans and mice, CHD has a low absolute sibling recurrence risk (∼2.7%)3, suggesting a considerable role for de novo mutations (DNMs) and/or incomplete penetrance4,5. De novo protein-truncating variants (PTVs) have been shown to be enriched among the 10% of 'syndromic' patients with extra-cardiac manifestations6,7. We exome sequenced 1,891 probands, including both syndromic CHD (S-CHD, n = 610) and nonsyndromic CHD (NS-CHD, n = 1,281). In S-CHD, we confirmed a significant enrichment of de novo PTVs but not inherited PTVs in known CHD-associated genes, consistent with recent findings8. Conversely, in NS-CHD we observed significant enrichment of PTVs inherited from unaffected parents in CHD-associated genes. We identified three genome-wide significant S-CHD disorders caused by DNMs in CHD4, CDK13 and PRKD1. Our study finds evidence for distinct genetic architectures underlying the low sibling recurrence risk in S-CHD and NS-CHD.

26 February 2012 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
JHJeroen K J Van Houdt
Jeroen K J Van Houdt
BNBeata Anna Nowakowska
Beata Anna Nowakowska
SSSérgio B Sousa
Sérgio B Sousa
BSBarbera D C van Schaik
Barbera D C van Schaik
ESEve Seuntjens
Eve Seuntjens
JVJoris Robert Vermeesch
Joris Robert Vermeesch

5 October 2015 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
TSthe DDD study
the DDD study
NANadia Akawi
Nadia Akawi
JMJeremy McRae
Jeremy McRae
MAMorad Ansari
Morad Ansari
Meena BalasubramanianMeena Balasubramanian
Meena Balasubramanian
MHMatthew E Hurles
Matthew E Hurles

15 November 2023 in Nature
Verified
Journal Article
Closed access
PDF file
NBNordin Bansaccal
Nordin Bansaccal
PVPauline Vieugue
Pauline Vieugue
RSRahul Sarate
Rahul Sarate
YSYura Song
Yura Song
EMEsmeralda Minguijon
Esmeralda Minguijon
CBCédric Blanpain
Cédric Blanpain

1 December 2015 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
MIMala Isrie
Mala Isrie
MBMartin W Breuss
Martin W Breuss
GTGuoling Tian
Guoling Tian
AHAndi Harley Hansen
Andi Harley Hansen
FCFrancesca Cristofoli
Francesca Cristofoli
HEHilde Van Esch
Hilde Van Esch